Compared with Q4 2025, management shifted from “well on track to initiate dosing” (Q4) to confirming enrollment and dosing are underway (Q1): Payne said in Q1, “Our 12-week Phase II study began enrollment in Q1,” versus Q4’s “We are well on track to initiate dosing for this Phase II 12-week study in the first half of this year.”

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago. These figures are adjusted for non-recurring items.

Over the next week skywatchers can expect to see a brilliant star that sparkles with a golden yellow or topaz hue that is situated about one-third of the way up from the eastern horizon as darkness falls. This is Arcturus, in the constellation of Boötes ...

Face east around 9-9:30 p.m. in mid-April and you can't miss shimmering orange Arcturus, the brightest star in the constellation Bootes the Bear Guardian. Two fists to the lower left of Arcturus, look for Corona Borealis (Northern Crown). Created with ...

Los Angeles County Department of Public Health confirmed three cases of the Arcturus strain with "observational data" suggesting that those infected may be likely to experience pink eye Alexis Jones is a writer-reporter at PEOPLE. She has been working at ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31,